ANAHEIM, Calif., Nov. 3, 2011 /PRNewswire/ -- Cempra Pharmaceuticals will be presenting data demonstrating Taksta's activity against Methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from cystic fibrosis (CF) patients and demonstrating solithromycin's anti-inflammatory activity in a human lung epithelial in vitro model at the 25th Annual North American Cystic Fibrosis Conference in Anaheim, California. Both studies will be presented during poster abstract sessions at 11:50 a.m. to 1:50 p.m. PDT, Nov. 3, and 4 to 6 p.m. PDT, Nov. 4, in Hall C in the Anaheim Convention Center.
Taksta (fusidic acid) is active against MRSA strains isolated from CF patients
Pulmonary MRSA infections in CF patients have been gaining increased attention because studies have shown that pulmonary function declines and mortality rates increase with MRSA infection. The prevalence of hospital-acquired or community-acquired MRSA in the respiratory tract of individuals with CF has increased dramatically. Fernandes et al. (Abst. # 285) investigated whether fusidic acid, shown to be active against MRSA isolated from other infections such as skin and skin structure infections, would be active against MRSA isolated from CF patients. Forty strains isolated from the sputum of CF patients were tested against fusidic acid and comparator antibiotics, such as vancomycin, linezolid and daptomycin. Fusidic acid demonstrated an MIC90 of 0.25 mg/L indicating that Taksta has potential for treating MRSA infection in CF patients.
Macrolides, including solithromycin (CEM-101), demonstrate anti-inflammatory activity in an airway anti-inflammation model
Macrolide antibiotics prolong survival in patients with diffuse panbronchiolitis, a condition that shares features with CF. Macrolides are known to have anti-inflammatory activity and it has been hypothesized that these immunomodulatory properties could me
|SOURCE Cempra Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved